Jazz commits up to $1.3B to buy Actio, bolster epilepsy pipeline

Jazz Pharmaceuticals to Acquire Actio Biosciences for Up to $1.32 Billion in Rare Epilepsy Deal

Jazz Pharmaceuticals announced a definitive agreement to acquire privately-held Actio Biosciences for $820 million upfront plus up to $500 million in milestone payments, gaining access to ABS-1230, an experimental treatment for KCNT1+ epilepsy, a rare inherited form of the disease with no approved therapies.